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Objective: To assess the efficacy and safety of
modified-release (MR) versus immediate-release (IR)
prednisone in newly diagnosed glucocorticoid (GC)-
naïve patients with polymyalgia rheumatica (PMR).
Methods: Patients were randomised to double-blind
MR prednisone (taken at approximately 22:00) or IR
prednisone (taken in the morning), 15 mg/day for
4 weeks. The primary end point was complete
response rate (≥70% reduction in PMR visual
analogue scale, duration of morning stiffness and C
reactive protein (CRP) (or CRP <2× upper limit of
normal (ULN))) at week 4. Non-inferiority was decided if
the lower 95% confidence limit (MR vs IR prednisone)
was above −15%. 400 patients were planned but only
62 were enrolled due to difficulties in recruiting GC-
naïve patients with PMR with CRP ≥2×ULN.
Results: The percentage of complete responders at
week 4 was numerically greater for MR prednisone
(53.8%) than for IR prednisone (40.9%). Non-
inferiority of MR versus IR prednisone was not proven
in the primary analysis on the per protocol population
(N=48; treatment difference: 12.22%; 95% CI
−15.82% to 40.25%). However, sensitivity analysis on
the full analysis population showed an evident trend
favouring MR prednisone (N=62; treatment difference:
15.56%; 95% CI −9.16% to 40.28%). Adverse events
were generally mild and transient with no unexpected
safety observations.
Conclusions: The study showed a clear trend for
favourable short-term efficacy of MR prednisone versus
IR prednisone in early treatment of PMR. Further
studies are warranted.
Trial registration number: EudraCT number 2011-
002353-57; Results.
INTRODUCTION
Polymyalgia rheumatica (PMR) is a common
inflammatory rheumatic disease of older
people1 characterised by new-onset bilat-
eral shoulder and/or hip girdle pain with
pronounced stiffness and an acute phase
response.2 3 Glucocorticoids (GCs) are the
mainstay of treatment and rapidly improve PMR
symptoms;4 an initial flexible minimum effective
GC dose of 12.5–25 mg prednisone (recognising
demographics, comorbidities, comedications,
GC risk factors and disease severity) is recom-
mended by the 2015 European League Against
Rheumatism (EULAR) / American College of
Rheumatology (ACR) guidelines.5 6
Key messages
What is already known about this subject?
▸ Optimising the timing of glucocorticoid (GC)
administration in relation to endogenous cortisol
rhythms and symptom severity using modified-
release (MR) formulations can improve thera-
peutic potential in inflammatory conditions, as
already demonstrated in rheumatoid arthritis.
▸ Preliminary studies suggest that MR prednisone
may also have benefits in polymyalgia rheuma-
tica (PMR), but data from randomised controlled
trials are lacking.
What does this study add?
▸ This randomised controlled study showed a
clear trend for a larger reduction in key PMR
symptoms and levels of pro-inflammatory cyto-
kine interleukin (IL)-6 with MR prednisone com-
pared with immediate-release (IR) prednisone,
although only 62 of a planned 400 patients were
enrolled due to difficulties in recruiting GC-naïve
patients with PMR and the study did not meet
its primary objective of showing non-inferiority.
How might this impact on clinical practice?
▸ Results from this study, though limited, suggest
favourable efficacy of MR prednisone over IR pred-
nisone in patients with PMR, and further confirm-
ation should be sought from larger clinical trials.
▸ Experience from this study demonstrates that
careful consideration of PMR inclusion and
response criteria is required.
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Patients with inflammatory conditions such as PMR
typically show circadian variations in clinical symptoms
related to altered concentrations of inflammatory cyto-
kines, melatonin and cortisol, with key symptoms usually
most severe in the early morning.7–10 Modified-release
(MR) prednisone has been developed to optimise oral
GC treatment strategies with respect to circadian
rhythms of inflammation by releasing prednisone
∼4 hours after the administration of the tablet in the
late evening. The CAPRA (Circadian Administration of
Prednisone in Rheumatoid Arthritis) studies confirmed
that optimising the timing of GC administration improves
the benefit:risk ratio of long-term, low-dose GC treatment
in patients with rheumatoid arthritis (RA).10–12
Preliminary studies in PMR suggest that MR prednisone
may also have benefits in this inflammatory condition.13
This randomised, double-blind, active-controlled,
parallel-group, non-inferiority phase III clinical study
aimed to assess the efficacy and safety of evening MR
prednisone compared with morning administration of
immediate-release (IR) prednisone in newly diagnosed
patients initiating GC treatment for PMR.
METHODS
Setting, patients and treatments
The study (EudraCT number 2011-002353-57) was con-
ducted between March 2013 and March 2014 at 41
secondary care centres across nine European countries.
Patients aged ≥50 years, newly diagnosed with PMR and
previously untreated with GCs for PMR, were eligible for
inclusion. According to the 2012 EULAR/ACR provi-
sional classification criteria for PMR,14 15 the diagnosis
had to be confirmed by all of the following at screening:
(1) new-onset bilateral shoulder pain with/without hip
girdle pain; (2) a PMR visual analogue scale (VAS) score
≥50 (0–100 scale); (3) duration of morning stiffness
>45 min and (4) acute phase response shown by ele-
vated C reactive protein (CRP; ≥2 times the upper limit
of normal (ULN)). Patients were randomised in a 1:1
ratio to MR or IR prednisone for 4 weeks, and received
15 mg IR prednisone/placebo between 5:00 and 9:00
and 15 mg MR prednisone/placebo at 22:00±30 min. No
rescue medication was used, and other medications for
the treatment of PMR, including analgesics and coanal-
gesics, were prohibited during the study.
Study assessments
Every morning and evening, patients completed an elec-
tronic diary (Log Pad, PHT Corporation), recording
how their PMR had affected them (PMR VAS), their
overall pain (global pain VAS), pain in their arms and
shoulders (shoulder pain VAS), their overall level of
fatigue/tiredness (fatigue VAS), duration of morning
stiffness and time of medication intake. Interleukin-6
(IL-6), CRP and erythrocyte sedimentation rate (ESR)
were measured at baseline, week 1 (CRP/ESR only) and
week 4. Adverse events (AEs) were recorded throughout
the study.
Statistical analyses
The primary objective was to demonstrate non-inferiority
of MR prednisone administered in the evening versus IR
prednisone administered in the morning, with regard to
the percentage of complete responders at week 4
(primary end point). Complete response was defined as
≥70% improvement from baseline in PMR VAS, duration
of morning stiffness and CRP (or CRP <2×ULN)).16 The
primary end point was analysed using logistic regression
with treatment as a factor and baseline PMR VAS score,
duration of morning stiffness and CRP as covariates.
Non-inferiority was concluded if the lower limit of the
two-sided 95% CI was above −15%.
The primary analysis was performed using the per
protocol population (PPP) with sensitivity analysis per-
formed using the full analysis population (FAP; all rando-
mised patients who received ≥1 dose of study treatment).
Assuming a complete response rate of 69%16 in the com-
parator arm at week 4, an expected treatment difference
of 0%, a non-inferiority bound of −15%, 80% power and
a two-sided α of 0.05, a sample size of 300 patients in the
PPP (∼400 randomised patients) was required. Further




The study enrolled, randomised and treated 62 patients
(21 male patients, 41 female patients), all Caucasian,
with a mean age of 69 years (see online supplementary
table S1). All patients were included in the FAP and
safety population, while 48 patients (77.4%) were
included in the PPP. The study experienced a high
screen failure rate (62/124 patients screened), primarily
due to an insufficiently high CRP value (77% of screen
failures did not have CRP ≥2×ULN). The difficulties in
recruiting GC-naïve patients with PMR fulfilling the
inclusion criteria, and cessation of production of the
comparator Decortin 1 mg tablets, led to the premature
termination of the study after 11 months’ recruitment.
Participant flow is shown in figure 1.
Primary end point
The percentage of complete responders at week 4 was
numerically higher for MR prednisone (53.8%) than for
IR prednisone (40.9%, table 1), although non-inferiority
of MR versus IR prednisone was not proven in the
primary PPP analysis (treatment difference: 12.22% in
favour of MR prednisone; 95% CI −15.82% to 40.25%).
Sensitivity analysis on the FAP showed a trend in favour
of MR prednisone (treatment difference: 15.56%; 95%
CI −9.16% to 40.28%). The study was relevantly under-
powered (N=48 vs planned 300 patients in the PPP) due
to recruitment difficulties and early study termination.
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Secondary end points
A clear consistent trend for a larger favourable effect of
MR prednisone compared with IR prednisone was
observed for all secondary end points (except CRP and
ESR) at weeks 1 and 4 (table 2). The percentage of
responders (patients with ≥70% improvement from
baseline) was also greater for MR prednisone than for
IR prednisone at weeks 1 and 4 for all secondary end
points (see online supplementary table S2). Clinically
significant mean reductions and treatment differences
of more than 10 points in favour of MR prednisone were
observed for PMR VAS, global pain VAS and shoulder
pain VAS (table 2). MR prednisone was markedly more
effective than IR prednisone in reducing morning stiff-
ness duration from as early as week 1 (mean reduction
of 326 vs 160 min, table 2), which was supported by the
percentage of responders (44% vs 17%, online
supplementary table S2).
MR prednisone indicated good efficacy in reducing IL-6
levels compared with IR prednisone at week 4 (decrease
from baseline of −37.4 vs −29.8 pg/mL, table 2). Notable
reductions in CRP and ESR were observed in both
Figure 1 Participant flow.
Table 1 Response rates
Response Week









Complete response* (n (%)) 1 3 (11.5) 5 (15.6) 4 (18.2) 4 (13.3)
2 7 (26.9) 9 (28.1) 7 (31.8) 7 (23.3)
4 14 (53.8) 17 (53.1) 9 (40.9) 10 (33.3)
Partial response† (n (%)) 1 8 (30.8) 8 (25.0) 1 (4.5) 1 (3.3)
2 11 (42.3) 13 (40.6) 2 (9.1) 2 (6.7)
4 6 (23.1) 8 (25.0) 3 (13.6) 4 (13.3)
*Complete response was defined as all three of the following: (1) ≥70% improvement from baseline in the polymyalgia rheumatica visual
analogue scale, (2) ≥70% reduction in the duration of morning stiffness and (3) ≥70% reduction in the C reactive protein (CRP) value (or CRP
<2× upper limit of normal).
†Partial response was defined as two of the above three criteria being met.
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differencen Mean (SD)† n Mean (SD)†
PMR VAS (0–100 scale) Baseline 32 80.7 (12.88) 30 81.0 (11.70)
Week 1 31 −37.1 (25.70) 30 −28.2 (27.55) −9.3 (−22.97 to 4.30) 0.176
Week 4 27 −70.4 (20.81) 23 −59.8 (24.02) −12.8 (−22.58 to −3.05) 0.011
PMR VAS at awakening (0–100 scale) Baseline 32 81.7 (17.26) 30 85.9 (9.68)
Week 1 32 −36.6 (29.40) 30 −29.4 (29.78) −10.9 (−25.45 to 3.61) 0.138
Week 4 27 −70.7 (18.72) 23 −63.7 (23.25) −11.6 (−21.33 to −1.79) 0.021
Duration of morning stiffness (minutes) Baseline 32 530 (531.0) 30 616 (591.0)
Week 1 31 −326 (435.3) 30 −160 (412.4) 134.5 (18.50 to 250.50)‡ 0.021
Week 4 27 −457 (517.9) 23 −417 (574.7) 46.9 (−110.00 to 203.83)‡ 0.592
Global pain VAS (0–100 scale) Baseline 32 80.0 (13.14) 30 78.2 (13.96)
Week 1 31 −36.2 (26.73) 30 −27.1 (27.96) −7.5 (−21.10 to 6.11) 0.275
Week 4 27 −68.7 (21.73) 23 −55.5 (25.55) −13.6 (−23.23 to −3.26) 0.011
Global pain VAS at awakening (0–100 scale) Baseline 32 80.6 (18.94) 30 83.4 (13.13)
Week 1 32 −35.2 (30.03) 30 −28.5 (32.46) −9.1 (−23.78 to 5.57) 0.219
Week 4 27 −69.3 (20.67) 23 −60.9 (28.28) −12.3 (−23.23 to −1.42) 0.028
Shoulder pain VAS (0–100 scale) Baseline 32 81.0 (13.31) 30 79.9 (13.01)
Week 1 31 −36.9 (26.85) 30 −28.4 (28.67) −7.4 (−21.55 to 6.66) 0.295
Week 4 27 −68.4 (21.46) 23 −57.7 (25.92) −11.1 (−21.30 to −0.91) 0.033
Fatigue VAS (0–100 scale) Baseline 32 72.9 (19.31) 30 75.7 (14.31)
Week 1 31 −29.8 (24.94) 30 −24.6 (27.66) −7.8 (−20.67 to 5.07) 0.230
Week 4 27 −59.4 (27.34) 23 −57.6 (23.16) −6.4 (−16.76 to 4.05) 0.225
C reactive protein (mg/L) Baseline 32 50.6 (32.34) 30 69.6 (49.38)
Week 1 30 −40.8 (27.46) 30 −48.9 (44.27) −6.2 (−13.61 to 1.22) 0.100
Week 4 27 −44.0 (32.24) 23 −52.9 (48.33) −8.0 (−16.37 to 0.37) 0.060
Erythrocyte sedimentation rate (mm/hour) Baseline 32 66.5 (21.62) 30 68.3 (22.84)
Week 1 29 −25.8 (17.03) 35 −23.9 (15.29)
Week 4 31 −38.8 (24.14) 25 −40.1 (23.65) Not estimable§
Interleukin-6 (pg/mL) Screening 28 41.4 (34.97) 30 40.9 (35.18)
Week 4 19 −37.4 (41.27) 22 −29.8 (32.61) −6.5 (−11.84 to −1.23) 0.017
Larger decreases from baseline represent a favourable treatment effect for all secondary efficacy end points.
*Estimates are least square means with confidence limits from a repeated measures analysis of covariance model, if not stated otherwise.
†Raw mean at screening/baseline and mean change from baseline at weeks 1 and 4.
‡Estimates and confidence limits stem from the Hodges-Lehmann method.
§Convergence criteria not met.
















treatment groups, with a larger decrease for IR prednis-
one (although we noted that baseline CRP values were
higher in the IR prednisone group, and mean CRP
values at week 4 were lower for MR prednisone (8.4 mg/
L) than for IR prednisone (17.9 mg/L)).
Safety
The AEs reported during the study are presented in
online supplementary table S3. While more patients
experienced AEs in the MR prednisone group (19
(59%); 8 (25%) related) than the IR prednisone group
(9 (30%); 3 (10%) related), this was not driven by any
specific AEs and the majority of subjects in both treat-
ment groups experienced non-related AEs. Two patients
experienced serious AEs (pancytopenia and temporal
arteritis), which were not treatment-related. Three
patients prematurely discontinued due to AEs: upper
abdominal pain in the MR prednisone group and tem-
poral arteritis and burning sensation in the IR prednis-
one group (figure 1).
DISCUSSION
In this study, the complete response rate at week 4 was
numerically greater with MR prednisone (53.8%) than
with IR prednisone (40.9%). Non-inferiority of MR pred-
nisone versus IR prednisone was not proven for the
primary end point; however, even with only 48 patients
in the PPP (vs the 300 planned), the point estimate
was clearly in favour of MR prednisone and the lower
95% confidence limit was only marginally below
(−15.82%) the decided non-inferiority threshold of
−15%. Sensitivity analysis on the FAP supported the
trend in favour of MR prednisone, and secondary effi-
cacy results were encouraging, showing a clear consistent
trend for a stronger effect of MR prednisone compared
with IR prednisone. Of note, evening MR prednisone
was associated with significantly greater reductions in
IL-6 levels than morning IR prednisone, suggesting a
more effective downregulation of night cytokine synthe-
sis.17 These results are similar to findings in the CAPRA
studies in RA.10 12 Consistent with the CAPRA-1 study,
we observed no significant difference between MR pred-
nisone and IR prednisone on other inflammatory
markers (CRP and ESR).
The study experienced a higher than expected screen
failure rate (50%), primarily due to patients demonstrat-
ing lower CRP values not fulfilling the strict inclusion
criteria when referred. It appears that in suspected
PMR, primary care practitioners are willing to refer
GC-naïve only patients with mild elevation or normal
levels of inflammatory markers. However, it is likely that
this population may contain predominantly non-
inflammatory PMR mimics.18
The CAPRA studies have already confirmed that opti-
mising the timing of GC administration improves the
benefit:risk ratio of low-dose GC treatment in RA, and
the open-label extension of the CAPRA-1 study11 and
other publications19 20 confirmed positive long-term
effects. A recent clinical experimental study further sup-
ports the use of chronotherapy in PMR.9 Although the
formal criteria of non-inferiority were not met, our study
showed a clear trend for a favourable clinical effect of
MR prednisone over IR prednisone in patients with
PMR. Further confirmation should be sought from a
large clinical trial in patients with PMR, with careful con-
sideration of inclusion and response criteria, based on
the present study experience.
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